Optimizing Neurology Denial Management with Klivira

Effective neurology denial management is critical for neuro practices to maintain financial health and ensure patient access to vital treatments. Klivira's platform automates the complex process of appealing denials for high-cost neurology services and specialty medications.

Neurology practices frequently encounter prior authorization (PA) denials for high-cost specialty drugs, advanced imaging, and complex procedures. Managing these denials manually consumes significant staff time, leads to rework, and can delay patient care. Klivira provides an automated solution designed to integrate seamlessly into your existing revenue cycle, transforming how your team handles neurology claim denials and appeals.

Common Denial Triggers in Neurology

Neurology prior authorization is particularly dense with high-value, high-complexity services and medications that frequently trigger denials. These often include MS disease-modifying therapies (DMTs) like ocrelizumab or natalizumab, CGRP monoclonal antibodies for migraine prevention, anti-amyloid antibodies for Alzheimer's disease (e.g., lecanemab), and advanced imaging such as brain MRIs or amyloid PET scans. Each category comes with specific payer requirements that, if unmet, lead to denials.

Typical Neurology Services Prone to Denials

MS disease-modifying therapies (DMTs) – e.g., Ocrevus, Tysabri, Kesimpta
CGRP migraine prevention biologics – e.g., Aimovig, Ajovy, Emgality
Alzheimer's anti-amyloid antibodies – e.g., Leqembi, Kisunla
Botox for chronic migraine, spasticity, or dystonia
Advanced imaging (MRI, MRA, amyloid PET) and neuromodulation procedures (DBS, VNS)
Epilepsy specialty drugs (e.g., Xcopri, Briviact) and SMA/ALS treatments (e.g., Spinraza, Zolgensma)

Automated Denial Reason Parsing and Routing for Neurology

Klivira ingests denial information from all channels, including X12 835 remittance advice, X12 277 claim status, payer portals, and Da Vinci PAS `ClaimResponse` transactions. Our platform normalizes X12 CARC/RARC codes and payer-specific local variations into a uniform reason set. This automated parsing eliminates manual interpretation errors, ensuring that denials for specific neurology services—like a step-therapy requirement for an MS DMT or a missing amyloid biomarker confirmation for an Alzheimer's therapy—are correctly categorized and routed.

Streamlining Appeals for Neurology-Specific Documentation Gaps

Many neurology denials stem from documentation gaps, such as insufficient evidence of prior preventive trials for CGRP migraine biologics, or lack of McDonald criteria confirmation for MS DMTs. Klivira's automated appeal-packet assembly pulls relevant clinical documentation from your EMR via FHIR, including new lab results, updated problem lists, or notes added since the original PA submission. This ensures appeal packets for neurology services are robust, addressing specific payer requirements and AAN Practice Guidelines.

Proactive Timely Filing and Outcome Tracking for Neurology Appeals

Missing timely-filing windows is a common operational failure mode in manual denial management. Klivira enforces per-payer timely-filing windows for neurology appeals, providing proactive deadline surfacing and auto-escalation when appeal status remains unchanged. Appeal outcomes—whether overturn, partial overturn, or upheld—are written back to the EMR as DocumentReference and Communication resources, providing a comprehensive audit trail for downstream billing and clinical workflows.

Identifying Denial Patterns to Improve Upstream PA for Neurology

Klivira's platform provides granular reporting on denial patterns by payer, service line, and provider, offering critical insights for neurology practices. For example, if a specific payer consistently denies Botox for chronic migraine due to criteria gaps, this feedback loop enables your team to refine upstream PA submission processes, reducing future denials and improving overall PA accuracy for high-volume neurology treatments.

Frequently asked questions

How does Klivira handle step therapy denials for MS DMTs or CGRP migraine biologics?

Klivira's platform incorporates AAN-guideline-aware step-therapy logic to identify when a denial is due to unmet step-therapy requirements. It then automates the process of gathering documentation on prior therapy trials from the EMR via FHIR and assembling the appeal packet, ensuring compliance with payer-specific step-therapy protocols.

Can Klivira help with denials related to Alzheimer's anti-amyloid antibody therapies?

Yes, Klivira automates the documentation requirements for Alzheimer's anti-amyloid therapy prior authorizations and appeals. This includes verifying amyloid confirmation (PET or CSF), MRI for ARIA screening, and ApoE genotyping, addressing common denial reasons related to these specific clinical criteria.

What role does EMR integration play in neurology denial management?

Klivira leverages SMART on FHIR integration to pull essential clinical documentation directly from your EMR. For neurology appeals, this means automatically accessing patient history, diagnostic reports (e.g., MRI findings), headache diaries, or prior treatment records needed to substantiate medical necessity and overturn denials.

How does Klivira track the status of neurology appeals?

Klivira tracks appeal status across multiple channels, including payer portals, X12 277 transactions, and Da Vinci PAS. Our system provides real-time updates, enforces timely-filing windows, and can auto-escalate appeals that remain unresolved, preventing 'lost-to-follow-up' scenarios critical for chronic neurology treatments.

Does Klivira assist with peer-to-peer reviews for complex neurology denials?

For high-acuity clinical-necessity denials in neurology that require peer-to-peer review, Klivira streamlines the scheduling process. The platform routes scheduling requests to ordering clinicians and tracks the status, ensuring that these critical conversations occur within payer-specified timeframes.